Search results for "TERM-FOLLOW-UP"

showing 2 items of 2 documents

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

2010

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical manage…

Liver Cirrhosisthalassemiamedicine.medical_specialtyCirrhosisC VIRUS-INFECTION; HOMOZYGOUS BETA-THALASSEMIA; TRANSFUSION-DEPENDENT THALASSEMIA; TERM-FOLLOW-UP; IRON OVERLOAD; LIVER-DISEASE; INTERFERON-ALPHA; RISK-FACTORS; INTRAFAMILIAL TRANSMISSION; HEPATOCELLULAR-CARCINOMAHepatitis C virusThalassemiaImmunologymedicine.disease_causeChronic liver diseaseAntiviral AgentsBiochemistryHOMOZYGOUS BETA-THALASSEMIALiver diseaseHepatitis B ChronicLIVER-DISEASEHEPATOCELLULAR-CARCINOMAmedicineTRANSFUSION-DEPENDENT THALASSEMIAIRON OVERLOADHumansIntensive care medicineTERM-FOLLOW-UPchronic viral hepatitis; thalassemia; managementbusiness.industryCell BiologyHematologyHepatitis CHepatitis C ChronicHepatitis Bmedicine.diseaseINTRAFAMILIAL TRANSMISSIONchronic viral hepatitisImmunologyRISK-FACTORSINTERFERON-ALPHAViral hepatitisbusinessC VIRUS-INFECTIONmanagement
researchProduct

Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

2016

The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail.In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease.The study population included 157 patients (mean±sd age 49.4±14.1 years), with a mean±sd blood eosinophil count of 7.4±6.4×109 L−1 at diagnosis. There was a mean±sd of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corti…

MalePediatricsAdministration OralDiseaseChurg-Strauss SyndromeBronchoalveolar LavageSeverity of Illness Index0302 clinical medicineAdrenal Cortex HormonesEosinophilicEosinophiliaAged 80 and overNomenclatureSystemic VasculitisCohortMiddle AgedTerm-follow-upPrognosis3. Good healthRespiratory Function TestsManagementTreatment OutcomeCohortAntineutrophil cytoplasmic antibodiesPopulation studyFemaleFrancemedicine.symptomGranulomatosis with polyangiitisConsensus conferencePulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAdolescentVasculitides[ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology environment/HealthGranulomatosis03 medical and health sciencesYoung AdultEosinophiliamedicineHumansAnti-neutrophil cytoplasmic antibodyAsthmaAgedRetrospective Studies030203 arthritis & rheumatology[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/Healthbusiness.industryGranulomatosis with Polyangiitisasthmamedicine.diseaseEosinophils030228 respiratory systemImmunologybusinessTomography X-Ray Computed
researchProduct